Lidocaine Patches - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The lidocaine patches market size was valued at USD 603.74 million in 2025 and is estimated to grow from USD 649.02 million in 2026 to reach USD 931.75 million by 2031, at a CAGR of 7.5% during the forecast period (2026-2031). This report is segmented by Strength (4% Lidocaine Patches, and More), Product Type (Prescription, OTC), Adhesive Material (Aqueous, Non-Aqueous), Application (Post-Herpetic Neuralgia, Musculoskeletal, Lower-Back, Post-Surgical, Diabetic Neuropathic, and More), Distribution Channel (Hospital, Retail, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Lidocaine Patches Market Trends and Insights

Aging Population and Chronic Neuropathic Pain Burden

The lidocaine patches market is supported by an aging population with a higher prevalence of neuropathic and musculoskeletal pain. Adults aged 45 years and older face elevated risks of herpes zoster, post-herpetic neuralgia, osteoarthritis-related pain, and diabetic peripheral neuropathic pain. A 2025 clinical review reported that non-systemic options were increasingly preferred for frail adults because oral NSAIDs and opioids increased fall and drug interaction risks. These conditions support recurring demand for prescription and consumer lidocaine products. Japan demonstrated the commercial potential of topical pain-relief products in aging populations. Hisamitsu Pharmaceutical reported 4.5% year-over-year revenue growth in FY2026, driven by demand from older consumers. This performance indicates that consumer familiarity and retail availability can strengthen demand in aging markets. Manufacturers can benefit by offering convenient products aligned with older users’ safety requirements.

Preference for Non-Opioid Localized Pain Management

The lidocaine patches market benefits from the growing preference for non-opioid neuropathic pain management. Localized treatments target painful areas while limiting the systemic exposure associated with oral therapies. Researchers at Northeastern University reported that opioids had an efficacy rate below 20% for neuropathic pain, supporting alternative treatment approaches. Clinical and policy initiatives promoting localized pain management continue to support market demand. A claims analysis cited in Scilex’s 2025 annual report found that 21.3% of ZTlido users achieved at least a 20% reduction in opioid use, compared with 13.4% of generic 5% lidocaine patch users. The difference was statistically significant at P = 0.0008. The NOPAIN Act has provided separate Medicare Part B reimbursement for qualifying non-opioid treatments in hospital outpatient departments and ambulatory surgery centers since January 1, 2025. These reimbursement conditions can improve formulary placement and prescribing access for eligible products.

Generic Price Erosion and Formulary Substitution

Generic entry materially constrains the branded segment of the lidocaine patches market. In March 2025, the FDA approved the first generic lidocaine 1.8% patch. Aveva Drug Delivery Systems received approval for an AB-rated alternative to Scilex’s ZTlido. In August 2026, a Federal Circuit ruling affirmed a non-infringement finding, enabling Aveva’s planned commercial launch with 180 days of market exclusivity. The case concerned the interpretation of a dissolving-agent claim in ZTlido patents, increasing price competition as payers favor lower-cost alternatives. Prior authorization and formulary tiering can limit branded access, particularly under pharmacy benefit plans. While policy proposals addressing deductibles and step therapy may ease access barriers for approved non-opioid products, brands without a clear clinical or technical advantage face a higher substitution risk.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Over-the-Counter Self-Care Access
• Improved Patch Adhesion and Drug-Delivery Performance
• Adhesion Failure, Skin Irritation, and Heat-Related Delivery Variability

Segment Analysis

The 5% lidocaine patch held 58.45% of the lidocaine patches market share in 2025, supported by its established use in post-herpetic neuralgia and familiarity among pain specialists. A 2024 study of 24 patients reported that mean Visual Analogue Scale scores declined from 8.71 at baseline to 3.58 after four weeks of treatment. The format remains a formulary benchmark, although generic supply changes may pressure volumes. Its relevance depends on clinical familiarity, availability, and payer access.

Other strengths, including 1.8% and 10% systems, expanded prescriber dosage options. Bondlido 10% received approval in September 2025, while ZTlido 1.8% entered a new phase of generic competition during 2025 and 2026. The 4% format is forecast to grow at an 8.78% CAGR through 2031, driven by OTC availability across retail and online channels. Teva’s April 2026 exit from the 5% generic category may support demand for accessible 4% products. Companies need retail visibility, clear dosing, and consistent performance to drive repeat purchases.

Prescription products accounted for 76.56% of the lidocaine patches market share in 2025, reflecting their established use for post-herpetic neuralgia under FDA-labeled indications. Scilex reported that more than 206 million prescription lidocaine patches were sold in the United States during 2025. Tennessee Medicaid added ZTlido to its Preferred Drug List, extending coverage to 1.5 million enrollees. Growth will depend on clinical evidence, reimbursement coverage, and management of generic substitution.

OTC patches are forecast to grow at a 9.44% CAGR through 2031, supported by broad access to lower-strength products for routine pain relief. Manufacturers can build demand through retail placement, digital advertising, and direct-to-consumer channels. The April 2026 ITC investigation highlighted potential legal disruption to imported OTC supply. Domestic manufacturing, defensible drug-in-adhesive technology, and brand recognition may strengthen competitive positioning, while excessive price promotions could weaken long-term value.

Complete Report Scope:

• By Strength
  • 4% Lidocaine Patches
  • 5% Lidocaine Patches
  • Other Lidocaine Strengths
• By Product Type
  • Prescription Lidocaine Patches
  • Over-the-Counter Lidocaine Patches
• By Adhesive Material
  • Aqueous Adhesives
  • Non-Aqueous Adhesives
• By Application
  • Post-Herpetic Neuralgia
  • Musculoskeletal Pain
  • Lower-Back Pain
  • Osteoarthritis-Associated Pain
  • Post-Surgical Pain
  • Diabetic Neuropathic Pain
  • Sports and Exercise-Related Pain
  • Other Pain Indications
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.34% of the lidocaine patches market share in 2025, supported by established prescription infrastructure, a sizable aging population, and widespread use of topical pain treatments. The NOPAIN Act improved reimbursement for qualifying non-opioid products in hospital outpatient departments and ambulatory surgery centers from January 2025. Scilex Holding Company reported that more than 206 million prescription lidocaine patches were sold in the United States in 2025, with 6 principal manufacturers accounting for nearly 90% of prescription volume.

Europe maintains a meaningful position in the lidocaine patches market, supported by an aging population and a structured regulatory environment. Germany, Italy, and Spain have sizable patient populations with post-herpetic neuralgia and musculoskeletal pain management needs. European Medicines Agency bioequivalence requirements for transdermal patches support generic entry and cost control across national health systems, placing continued pressure on prescription product pricing.

Asia-Pacific is forecast to grow at a CAGR of 8.94% through 2031, making it the fastest-growing region in the lidocaine patches market. Japan and China combine aging populations with rising demand for accessible pain relief, while Southeast Asia is expanding access through retail distribution and broader OTC availability. Hisamitsu reported 4.5% FY2026 revenue growth and planned more than JPY 50 billion in Salonpas supply expansion, alongside over JPY 150 billion in research, development, and strategic investment. The supplied material cited these amounts as USD 323 million and USD 968 million, respectively. Hisamitsu launched Salonpas in Cambodia in May 2026 through a distribution agreement with Dynamic Argon Co., Ltd.

List of Companies Covered in this Report:

• Actavis Laboratories UT, Inc.
• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals
• Apotex
• Aveva Drug Delivery Systems
• Cipla
• DifGen Pharmaceuticals LLC
• Endo International
• Galen Limited
• Hisamitsu Pharmaceutical
• Mylan
• Nipro Pharma Corporation
• Oishi Koseido Co., Ltd.
• Scilex Pharmaceuticals Inc.
• Sparsha Pharma International Pvt. Ltd.
• Teikoku Seiyaku Co., Ltd.
• Teva Pharmaceutical Industries
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support